Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

100.30 -2.42 (-2.36%)
Official Closing Price Updated: 7:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
54 55 Next >
News headline image
Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever ↗
Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them. 
Via The Motley Fool
News headline image
Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables ↗
Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom. 
Via Stocktwits
News headline image
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q1 Earnings?
Abbott Laboratories has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 17.8% and now trades at $133.43. This performance may have investors... 
Via StockStory
Topics Stocks Supply Chain
News headline image
ABBOTT LABORATORIES (NYSE:ABT) – A Quality Stock Worth Considering ↗
ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and solid financial health, making it a stock worth considering for long-term portfolios. 
Via Chartmill
News headline image
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
Steady growth and dividend increases over decades can make investors remarkably wealthy. 
Via The Motley Fool
Topics Economy
News headline image
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued ↗
The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin... 
Via Stocktwits
News headline image
3 Low-Volatility Stocks in Hot Water
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Peering Into Abbott Laboratories's Recent Short Interest ↗
 
Via Benzinga
News headline image
1 Mooning Stock with Exciting Potential and 2 to Think Twice About
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
News headline image
ABBOTT LABORATORIES (NYSE:ABT) - A Strong Technical Setup for Breakout Investors ↗
ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality setup, making it a potential breakout candidate for traders. 
Via Chartmill
News headline image
3 Stocks With 3% to 9% Yields Just Raised Dividends Again
Via MarketBeat
News headline image
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges ↗
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
News headline image
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott ↗
The company said the regulatory path forward for one of its key systems is too murky to pursue. 
Via Investor's Business Daily
News headline image
2 Dividend Stocks to Buy With $500 and Hold Forever ↗
Via The Motley Fool
News headline image
ABBOTT LABORATORIES (NYSE:ABT) – A Quality Stock Worth Considering ↗
ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and excellent profit quality, making it a solid long-term candidate. 
Via Chartmill
News headline image
3 Magnificent Stocks That Are Passive Income Machines ↗
Via The Motley Fool
News headline image
What's going on in today's session: S&P500 movers ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
Via Get News
Topics Death Economy
News headline image
Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock ↗
 
Via Benzinga
News headline image
ABBOTT LABORATORIES (NYSE:ABT) - A Strong Technical Setup for Breakout Investors ↗
ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality breakout setup, supported by institutional interest and clear support/resistance levels. 
Via Chartmill
News headline image
Reflecting On Medical Devices & Supplies - Diversified Stocks’ Q1 Earnings: Abbott Laboratories (NYSE:ABT)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Abbott Laboratories... 
Via StockStory
News headline image
1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
News headline image
Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know ↗
The Milken Institute's 28th annual Global Conference, featuring prominent figures like Jensen Huang, Magic Johnson, and Linda Yaccarino, is focusing on key global issues such as AI, healthcare, and... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now ↗
Via The Motley Fool
Topics Government Stocks World Trade
News headline image
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio? ↗
Via The Motley Fool
News headline image
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again? ↗
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
News headline image
Abbott Laboratories (NYSE:ABT) Shows Strong Technical Breakout Potential ↗
Abbott Laboratories (NYSE:ABT) Shows Strong Technical Breakout Potential 
Via Chartmill
News headline image
A Look Into Abbott Laboratories Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
3 Dividend Stocks to Buy and Hold for the Next Decade ↗
Via The Motley Fool
News headline image
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio. 
Via MarketBeat
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.